Schizophrenia affects approximately 24 million people worldwide, or 1 in every 300 people (0.32%). In adults, this rate is 1 in 222 (0.45%). It is not as widespread as many other mental disorders. Onset occurs most frequently in late adolescence and the twenties, and it occurs earlier in men than in women.

Schizophrenia is frequently associated with significant distress and impairment in important areas of life such as personal, family, social, educational, occupational, and other. People with schizophrenia are twice as likely as the general population to die young. This is frequently due to physical illnesses such as cardiovascular, metabolic, and infectious diseases.

DelveInsight estimates that in 2021, the highest schizophrenia prevalence was observed in the United States, followed by other European countries, and the lowest prevalence of schizophrenia was in Japan. According to DelveInsight’s estimates, the United States accounted for approx 3 million cases of schizophrenia in the year 2021, followed by approx 2 million cases in the EU5 and 1 million cases in Japan.

Schizophrenia Epidemiology Forecast – 2032

 

A person with schizophrenia can have symptoms like delusions, hallucinations, disorganized speech, trouble with thinking, and might feel demotivated. It is a disorder with variable phenotypic expression and poorly understood, complex etiology, involving a major genetic contribution, as well as environmental factors interacting with the genetic susceptibility.

Despite its antiquity, most of what is known about schizophrenia has been discovered over the past 10 decades, mostly in the late twenties and early twenty-first centuries. A lot of research has been going on to give a clearer picture of the illness. However, despite a century of research, the pathophysiology of schizophrenia remains elusive.

Diagnostic scales, which have been extensively validated, are widely used within clinical practice and research settings. Two key examples include the American Psychiatric Association’s Diagnostic and Statistical Manual (DSM) and the World Health Organization’s International Classification of Diseases (ICD).

Both the DSM, for which at least two schizophrenia symptoms including delusions, hallucinations, disorganized speech and behavior, and negative symptoms need to have been present for at least six months and for a significant portion of time over one month, and the ICD for which at least two schizophrenia symptoms must be present, including positive, negative, depressive, manic, psychomotor, and cognitive symptoms. Of the two schizophrenia symptoms, one core symptom needs to be present. Schizophrenia symptoms should have been present most of the time during a period of at least one month. These criteria are regularly updated, and the most recent versions are the DSM-5 and the ICD-11.

Schizophrenia Multimodal Treatment Strategy

Schizophrenia Management Strategy
Important Strategies in Schizophrenia Management

Despite therapeutic advancements in recent decades, schizophrenia remains one of the most severe mental illnesses, with a chronic relapsing course and significant functional impairment in a significant number of individuals. Currently, there is no cure for schizophrenia. However, the disorder is treated and manageable with a combination of schizophrenia therapies. Although the aim of schizophrenia treatment varies depending on severity and phase, but the short-term primary goal of schizophrenia treatment is to control symptoms. The primary goal is to manage psychotic symptoms and enhance patients’ quality of life (QoL). However, the long-term objective of schizophrenia treatment is to achieve stability and avoid sickness return.

The Goal of Schizophrenia Treatment

Schizophrenia Treatment: Major Unmet Need to Address
Key Unmet Needs in the Schizophrenia Treatment

The current pyramid of interventions in managing schizophrenia includes antipsychotic medications, the most commonly prescribed schizophrenia drugs and thought to control symptoms by affecting the brain neurotransmitter dopamine. Even after symptoms have faded, schizophrenia requires lifetime therapy. Apart from schizophrenia medications, psychological counseling, and social support, cognitive behavioral therapy and electroconvulsive therapy (ECT) can be used to control the condition. Hospitalization may be required in some circumstances.

Schizophrenia treatment is generally guided by a psychiatrist with expertise in treating schizophrenia, including a psychologist, social worker, or psychiatric nurse. Although therapy objectives such as response, remission, and recovery have become more generally defined, a reliable "effectiveness" metric that maps onto functional outcomes remains missing. Furthermore, the field must progress in translating measurement-based techniques from research to clinical practice. Adding to this debate is continuous disagreement about whether first-generation or second-generation antipsychotics should be used.

Key Differences Between First and Second Generation Antipsychotics

Schizophrenia: First-Generation & Second-Generation Antipsychotics Analysis
Key Insights into the First and Second Generation Antipsychotics for Schizophrenia

Antipsychotics (APs) are the first-line therapy for schizophrenia on the market. These are divided into two categories: first-generation antipsychotics (FGA; or conventional APs) and second-generation antipsychotics (SGA) (SGA; or atypical APs). These are either administered orally for oral antipsychotics (OAP) or intravenously for long-acting injectable schizophrenia treatments (LAI). Although both FGA and SGA are used for schizophrenia treatment, the usefulness of the second generation over the first is controversial, as is the effectiveness of LAI over OAP.

Key First and Second Generation Antipsychotics
Major FGA and SGA for Schizophrenia Treatment

However, when evaluating individual adverse effect profiles, the distinction between first- and second-generation antipsychotics as unified classes cannot be maintained, requiring a more differentiated approach and schizophrenia treatment decision. The intended, tailored schizophrenia treatment strategy must take present symptoms, comorbid diseases, previous therapeutic responses, adverse effects, and patient preference and expectations into account.

Today, at the global level, some of the key companies, such as Boehringer Ingelheim, Karuna Therapeutics, Acadia Pharmaceuticals, Reviva Pharmaceuticals, Sunivion, PsychoGenics, Otsuka Pharmaceuticals,  Neurocrine Biosciences, Takeda, Newron Pharmaceuticals, Lyndra Therapeutics, Pharmaceuticals Laboratories, Cerevel Therapeutics, and others, are evaluating various therapies in different schizophrenia clinical trials to improve the treatment space. 

Currently, the therapies in the schizophrenia pipeline include ICLEPERTIN (BI-425809), KarXT (Xanomeline-Trospium), NUPLAZID (pimavanserin), Brilaroxazine (RP-5063), ULOTARONT (SEP-363856), LUVADAXISTAT (NBI 1165844/TAK 831), Evenamide (NW-3509/NW-3509A), LYN-005 (risperidone, weekly), OKEDI (risperidone ISM), Emraclidine (CVL-231), and others. The launch of these therapies in the schizophrenia treatment market in the coming years will significantly improve people’s lives affected by schizophrenia.

Moreover, the global prevalence of schizophrenia has observed stable growth in the past two decades, and the same stable growth is expected in the coming years. Governments and health organizations must raise awareness to make schizophrenia patients comfortable to combat mental illness and raise awareness of the long-term repercussions. However, due to the side effects of the antipsychotic schizophrenia medication, compliance is quite less, and it is a challenge for the caregivers to tackle this issue. Despite antipsychotic therapy, schizophrenia is linked with considerable unmet medical demands, functional impairments, and a high burden of illness. One of the biggest impediments to treatment effectiveness in schizophrenia is medication non-compliance. Non-adherence is prevalent, with outcomes including insufficient symptom management, relapse, hospitalization, and increased consumption and expense of health care resources.

Compliance of Schizophrenia Patients

Compliance to Schizophrenia Treatment
Treatment Compliance for Schizophrenia Management

Schizophrenia patients who stop using antipsychotic medications maybe two to five times are more likely to relapse than other schizophrenia patients. Although the causes for medication non-adherence are varied, the failure to stay on schizophrenia medicine jeopardizes the chance of remission and better functioning in people with schizophrenia. To date, clozapine is the only evidence-based treatment for refractory schizophrenia patients, and the role of antipsychotic polypharmacy and other augmentation strategies remains unclear at best.

Schizophrenia Treatment Landscape

Evolving Schizophrenia Treatment Landscape
Key Developments in the Schizophrenia Treatment Space

To discover novel schizophrenia treatments with enhanced/broader efficacy and improved tolerability, and to enable personalized treatment, the mechanisms underlying illness development and progression, symptomatic improvement, and side effect development need to be elucidated. Most people with schizophrenia benefit from combined antipsychotic medication and non-pharmacologic treatments that address their personal goals. Several promising approaches for improving outcomes in schizophrenia are under study that may help mitigate persistent psychotic symptoms, negative symptoms, and cognitive deficits in patients with established illnesses. Attention is being focused on the early administration of psychosocial interventions to reduce persistent disability.

Nevertheless, after over a century of schizophrenia treatment, significant progress has been made, starting from the lobotomy operations, through the discovery of chlorpromazine, to current second and third- generation antipsychotics. Novel approaches, following new studies in the disease mechanisms, will finally result in a new generation of schizophrenia drugs.

As per DelveInsight analysis, the schizophrenia market size in the 7MM is expected to change during the study period (2019–2032). In 2021, the total schizophrenia market size was USD 8,664.6 million, which is expected to rise by 2032.

Furthermore, the WHO’s Comprehensive Mental Health Action Plan 2013–2030 will raise mental health awareness by ensuring that 100 million more people have access to quality and affordable mental health care.

Schizophrenia Treatment Scenario

FAQs

1. What is schizophrenia?

Schizophrenia is a word that has been around for over a century, and it has always perplexed scientific communities. A chronic psychotic disorder, schizophrenia, meddle with the patient’s thoughts, interferes with a patient’s social ability, and hampers cognitive development.

2. What are symptoms of schizophrenia?

Schizophrenia symptoms include delusions, hallucinations, disorganized speech, trouble with thinking, and feeling of demotivation. It is a disorder with variable phenotypic expression and poorly understood, complex etiology, involving a major genetic contribution, as well as environmental factors interacting with the genetic susceptibility.

3. How is schizophrenia diagnosed?

Schizophrenia is diagnosed by ruling out other mental health disorders and determining that symptoms are not caused by substance abuse, medication, or a medical condition. A physical exam, blood tests, screening, including CT scan and MRI, and psychiatric evaluation using the schizophrenia symptoms diagnosis scale (PANSS, CGI, SANS, etc.) may be used for the schizophrenia diagnosis.

4. What causes schizophrenia?

The exact causes of schizophrenia are unknown. According to research, a combination of physical, genetic, psychological, and environmental factors can increase a person’s risk of developing the condition. Some people are predisposed to schizophrenia, and a stressful or emotionally charged life event may set off a psychotic episode.

5. What is the goal of schizophrenia treatment?

The current pyramid of interventions in managing schizophrenia includes antipsychotic medications, the most commonly prescribed schizophrenia drugs, and thought to control symptoms by affecting the brain neurotransmitter dopamine. Even after symptoms have faded, schizophrenia requires lifetime therapy. Apart from schizophrenia medications, psychological counseling, and social support, cognitive behavioral therapy and electroconvulsive therapy (ECT) can be used to control the condition. Hospitalization may be required in some circumstances.

6. Where is schizophrenia most prevalent?

DelveInsight estimates that in 2021, the highest schizophrenia prevalence was observed in the United States, followed by other European countries, and the lowest prevalence of schizophrenia was in Japan.

7. Which pharma companies are working in the schizophrenia market?

Today, at the global level, some of the key companies, such as Boehringer Ingelheim, Karuna Therapeutics, Acadia Pharmaceuticals, Reviva Pharmaceuticals, Sunivion, PsychoGenics, Otsuka Pharmaceuticals,  Neurocrine Biosciences, Takeda, Newron Pharmaceuticals, Lyndra Therapeutics, Pharmaceuticals Laboratories, Cerevel Therapeutics, and others, are involved in developing therapies for schizophrenia treatment.

8. How the schizophrenia pipeline looks like?

Currently, promising therapies in the schizophrenia pipeline include ICLEPERTIN (BI-425809), KarXT (Xanomeline-Trospium), NUPLAZID (pimavanserin), Brilaroxazine (RP-5063), ULOTARONT (SEP-363856), LUVADAXISTAT (NBI 1165844/TAK 831), Evenamide (NW-3509/NW-3509A), LYN-005 (risperidone, weekly), OKEDI (risperidone ISM), Emraclidine (CVL-231), and others.